Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for GILD, sign up here.
Income Statement
Revenue
$27.1bn
Gross Profit
$20.6bn
Earning before Tax
$6.9bn
Net Income
$5.7bn
Net Income Common Shareholders
$5.7bn
EPS
4.54
Balance Sheet
Cash
$6.1bn
Debt
$25.0bn
Assets
$62.1bn
Liabilities
$39.4bn
Equity
$22.8bn
Enterprise Value
$120.2bn
Cash Flow Statement
Net Cash from Operations
$8.0bn
Net Cash from Investing
$-2.3bn
Net Cash from Financing
$-5.1bn
Net Cash Flow
$673.0m
Free Cash Flow
$7.4bn
Free Cash Flow per Share
$5.95
Metrics
Price to Equity
17.82
Price to Equity (Damodaran)
17.84
Price to Book
4.42
Net Margin
0.21
Return on Equity
0.26
Return on Sales
0.29
Get immediate access to 5-years of reference grade data for GILD for free.
Sign upGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Info
Industry
Drug Manufacturers - General
Employees
Address
333 Lakeside Drive
Foster City, CA 94404
United States
Phone
650 574 3000
Website
Last Updated
2024-02-19
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.